Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.
The world's largest generic drugmaker has been looking to expand its specialty portfolio and said it is seeking more than 400 new laboratories within Israeli academia.
Follow Israel Hayom on Facebook and Twitter
A partnership with Tel Aviv University will focus on research and development in cancer and brain studies, while a collaboration with the Weizmann Institute of Science will try to identify antibodies for cancer treatment, Israel-based Teva said.
"Teva is planning to carry out much more cutting-edge collaboration with researchers from leading universities and medical centers in Israel in the fields of oncology, immunology and brain studies – areas in which Israel has unique research capabilities," said Steffen Nock, head of Teva's innovative research team.
